Search results for "Numbers Needed To Treat"

showing 2 items of 2 documents

Relative risk rather than absolute risk reduction should be preferred to sensitise the public to preventive actions.

2021

We thank Lawrence and colleagues1 for their interest in our work,2 about which they raised some comments as the need of expressing results in absolute rather than relative risks. As they appropriately mentioned in their correspondence, absolute risk is an important parameter for the estimation of the effect of an intervention and must sometimes be preferred to relative risk. However, when discussing with health professionals and policymakers, using absolute risk reductions, expressed as percentages, may incorrectly lead to an intervention being considered unnecessary. As example, what would be the point of reducing by 30% the occurrence of an event affecting 2% of the population? This is ex…

0301 basic medicineEstimationRiskeducation.field_of_studyActuarial scienceCancer preventionCoronavirus disease 2019 (COVID-19)PopulationGastroenterologyAbsolute risk reductionDiscount points03 medical and health sciences030104 developmental biology0302 clinical medicineIntervention (counseling)Relative riskHumans030211 gastroenterology & hepatologyeducationPsychologyNumbers Needed To TreatGut
researchProduct

Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From …

2021

Background: Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Previous lower extremity revascularization (LER) is associated with increased ALI risk in chronic PAD. However, the pattern of risk, clinical correlates, and outcomes after ALI early after LER are not well-studied, and effective therapies to reduce ALI post-LER are lacking. Methods: The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD; rNCT02504216) randomized patients with PAD undergoing LER to rivaroxa…

Malemedicine.medical_specialtymedicine.medical_treatmentPlaceboRevascularizationRivaroxabanIschemiaperipheral arterial diseasePhysiology (medical)Internal medicinemedicineHumansCumulative incidenceMyocardial infarctionrivaroxabanthrombosisAgedRivaroxabanAspirinbusiness.industryHazard ratioMiddle Agedmedicine.diseaseClopidogrelrespiratory tract diseasesLower ExtremityAmputationAcute Diseaselower extremityCardiologyFemaleCardiology and Cardiovascular MedicinebusinessNumbers Needed To Treatmedicine.drugCirculation
researchProduct